Immunotherapy Biomarkers
Section edited by Lisa H. Butterfield, PhD
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.
- RESEARCH ARTICLE
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes the de...Journal for ImmunoTherapy of Cancer 2017 5:81Published on: 17 October 2017 - RESEARCH ARTICLE
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocy...Journal for ImmunoTherapy of Cancer 2017 5:82Published on: 17 October 2017 - RESEARCH ARTICLE
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab
Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to...Journal for ImmunoTherapy of Cancer 2017 5:67Published on: 15 August 2017 - RESEARCH ARTICLE
Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination
Immunotherapies have demonstrated clinical benefit for many types of cancers, however many patients do not respond, and treatment-related adverse effects can be severe. Hence many efforts are underway to ident...Journal for ImmunoTherapy of Cancer 2017 5:56Published on: 18 July 2017 - RESEARCH ARTICLE
Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy
Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T ce...Journal for ImmunoTherapy of Cancer 2017 5:33Published on: 18 April 2017 - MEETING REPORT
Immunotherapy biomarkers 2016: overcoming the barriers
This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cospon...Journal for ImmunoTherapy of Cancer 2017 5:29Published on: 21 March 2017 - RESEARCH ARTICLE
Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (...Journal for ImmunoTherapy of Cancer 2017 5:25Published on: 21 March 2017 - RESEARCH ARTICLE
Gene expression markers of Tumor Infiltrating Leukocytes
Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the in...Journal for ImmunoTherapy of Cancer 2017 5:18Published on: 21 February 2017 - RESEARCH ARTICLE
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-depend...Journal for ImmunoTherapy of Cancer 2017 5:20Published on: 21 February 2017 - RESEARCH ARTICLE
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor. In this context, we recently reported on the levels...Journal for ImmunoTherapy of Cancer 2016 4:75Published on: 15 November 2016 - REVIEW
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, there have been many clinical successes using checkpoint receptor blockade, including T cell inhibi...Journal for ImmunoTherapy of Cancer 2016 4:76Published on: 15 November 2016 - REVIEW
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations
There is growing recognition that immunotherapy is likely to significantly improve health outcomes for cancer patients in the coming years. Currently, while a subset of patients experience substantial clinical...Journal for ImmunoTherapy of Cancer 2016 4:77Published on: 15 November 2016 - SHORT REPORTJournal for ImmunoTherapy of Cancer 2016 4:57Published on: 20 September 2016
- RESEARCH ARTICLE
Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients
Preclinical studies suggest a synergistic effect between radiation, immunotherapy and anti-angiogenic therapy, although the mechanisms are unclear. Angiogenic cytokines are known to affect the immune system, a...Journal for ImmunoTherapy of Cancer 2016 4:32Published on: 21 June 2016 - RESEARCH ARTICLE
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
Depletion of CD25+ Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25+ T cells. Prior ...Journal for ImmunoTherapy of Cancer 2016 4:35Published on: 21 June 2016 - SHORT REPORTJournal for ImmunoTherapy of Cancer 2016 4:22Published on: 19 April 2016
- SHORT REPORTJournal for ImmunoTherapy of Cancer 2016 4:18Published on: 15 March 2016
- SHORT REPORTJournal for ImmunoTherapy of Cancer 2016 4:9Published on: 16 February 2016
- SHORT REPORTJournal for ImmunoTherapy of Cancer 2016 4:2Published on: 19 January 2016
- SHORT REPORTJournal for ImmunoTherapy of Cancer 2015 3:42Published on: 15 December 2015
.png)
No hay comentarios:
Publicar un comentario